Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.50 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455757 | 1.00 | DPP4 (0.50) | DPP4F2KCNA5HTR2ATAAR1 | |
| SCHEMBL1052063 | 1.00 | DPP4 (0.50) | DPP4F2KCNA5HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL8390398 | 0.97 | DPP4 (0.48) | DPP4F2KCNA5HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL4708717 | 0.97 | DPP4 (0.48) | DPP4F2KCNA5HTR2ATAAR1 | |
| Hydrochloric Acid SCHEMBL5845127 | 0.97 | DPP4 (0.48) | DPP4F2KCNA5HTR2ATAAR1 | |
| SCHEMBL4514361 | 0.86 | CHRNB2 (0.47) | DPP4F2TAAR1ALDH1A1 | |
| SCHEMBL5843823 | 0.86 | CHRNB2 (0.47) | DPP4F2TAAR1ALDH1A1 | |
| SCHEMBL15228144 | 0.80 | DPP4 (0.46) | DPP4F2KCNA5HTR2ATAAR1 | |
| SCHEMBL296872 | 0.77 | IDO1 (0.44) | — | |
| SCHEMBL14305986 | 0.77 | IDO1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 479 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122094389-A | Perovskite material, perovskite layer, preparation method of perovskite layer, perovskite solar cell and photovoltaic module | — | 2026-05-26 | — | — | CN | claimed |
| CN-114420852-B | Preparation method of pure-phase RP perovskite film | 河北工业大学 | 2025-05-27 | — | — | CN | claimed |
| WO-2024196936-A2 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. (US) | 2024-09-26 | — | — | WO | claimed |
| US-20240322244-A1 | LOCALIZED HIGH CONCENTRATION ELECTROLYTE AND LITHIUM-ION BATTERY COMPRISING THE SAME | SILA NANOTECHNOLOGIES, INC. | 2024-09-26 | — | — | US | claimed |
| EP-2532663-B1 | Naphthalenetetracarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2016-03-16 | — | — | EP | claimed |
| EP-2532663-A1 | Naphthalenecarboxylic acid derivatives and their use as semiconductors | BASF SE (DE) | 2012-12-12 | — | — | EP | claimed |
| EP-1865963-A2 | TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR | Acadia Pharmaceuticals Inc. (US) | 2007-12-19 | — | — | EP | claimed |
| WO-2006089286-A2 | TRIAZADIBENZOAZULENE COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR COMPOUNDS USEFUL FOR THE TREATMENT AND PREVENTION OF PAIN AND SCREENING METHODS THEREFOR | ACADIA PHARMACEUTICALS INC. (US) | 2006-08-24 | — | — | WO | claimed |
| EP-1307200-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | Wyeth (US) | 2003-05-07 | — | — | EP | claimed |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | AMERICAN HOME PRODUCTS CORPORATION | 2002-06-06 | — | — | US | claimed |
| US-6376712-B2 | REDUCTION OF THE CORRESPONDING OXIME COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-23 | — | — | US | claimed |
| US-6362372-B2 | HYDROGENATION OF A TRIFLUOROBENZYLNITRILE BY HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA AND A CATALYST COMPRISING A PLATINUM GROUP ELEMENT; EXTREMELY HIGH YIELDS | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-03-26 | — | — | US | claimed |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-31 | — | — | US | claimed |
| US-20020007086-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-17 | — | — | US | claimed |
| WO-2002002563-A2 | SUBSTITUTED-TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS | WYETH (US) | 2002-01-10 | — | — | WO | claimed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| US-6175041-B1 | HYDROGENATING A TRIFLUOROMETHYLBENZONITRILE WITH HYDROGEN IN AN ORGANIC SOLVENT IN THE PRESENCE OF AMMONIA, USING A RANEY CATALYST | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-01-16 | — | — | US | claimed |
| JP-63270631-A | — | — | None | — | — | JP | disclosed |
| US-4267345-A | 2-//PYRROL-2-YL, THIEN-2-YL, OR FUR-2-YL/-ALPHA-TRIFLUOROALKYL-AMINOOXAZOLINES; HYPOTENSIVE AGENTS | SCIENCE UNION ET CIE (FR) | 1981-05-12 | — | — | US | disclosed |
| US-4132737-A | ENZYME INHIBITORS | ELI LILLY AND COMPANY (US) | 1979-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007086-A1 | Process for producing trifluoromethylbenzylamines | IDH1, INMT, TH | DPP4 3589/4885F2 360/4885KCNA5 991/4885 |
| US-20020068744-A1 | Substituted-triazolopyrimidines as anticancer agents | TUBB3, TUBA1C, TUBB1 | DPP4 2165/4885F2 4836/4885KCNA5 3799/4885 |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | MAOB, CYP2F1, AGL | DPP4 4783/4885F2 506/4885KCNA5 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.